Quarterly Net Income
The latest quarterly quarterly net income is $91.10M with a quarterly period change of (10.33%). Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.
PODD Quarterly Net Income
Reported quarterly net income; no daily interpolation.
Quarterly Net Income History
| Period | Quarterly Net Income | % Change |
|---|---|---|
| Q1 2026 | $91.10M | (10.33%) |
| Q4 2025 | $101.60M | +15.98% |
| Q3 2025 | $87.60M | +289.33% |
| Q2 2025 | $22.50M | (36.44%) |
| Q1 2025 | $35.40M | (64.85%) |
| Q4 2024 | $100.70M | +29.94% |
| Q3 2024 | $77.50M | (58.91%) |
| Q2 2024 | $188.60M | +266.21% |
| Q1 2024 | $51.50M | (50.15%) |
| Q4 2023 | $103.30M | +99.04% |
| Q3 2023 | $51.90M | +90.11% |
| Q2 2023 | $27.30M | +14.71% |
| Q1 2023 | $23.80M | +40.00% |
| Q4 2022 | $17.00M | +426.92% |
| Q3 2022 | ($5.20M) | +85.14% |
| Q2 2022 | ($35.00M) | (225.90%) |
| Q1 2022 | $27.80M | (4.79%) |
| Q4 2021 | $29.20M | +131.75% |
| Q3 2021 | $12.60M | +150.40% |
| Q2 2021 | ($25.00M) | (4266.67%) |
| Q1 2021 | $600,000 | +103.51% |
| Q4 2020 | ($17.10M) | (247.41%) |
| Q3 2020 | $11.60M | (19.44%) |
| Q2 2020 | $14.40M | +785.71% |
| Q1 2020 | ($2.10M) | (142.27%) |
| Q4 2019 | $4.97M | +521.00% |
| Q3 2019 | $800,000 | (42.86%) |
| Q2 2019 | $1.40M | (68.18%) |
| Q1 2019 | $4.40M | (55.52%) |
| Q4 2018 | $9.89M | +496.32% |
| Q3 2018 | $1.66M | +198.11% |
| Q2 2018 | ($1.69M) | +74.26% |
| Q1 2018 | ($6.57M) | +4.24% |
| Q4 2017 | ($6.86M) | (208.04%) |
| Q3 2017 | ($2.23M) | +71.33% |
| Q2 2017 | ($7.77M) | +22.15% |
| Q1 2017 | ($9.98M) | (9.41%) |
| Q4 2016 | ($9.12M) | (195.98%) |
| Q3 2016 | ($3.08M) | +26.61% |
| Q2 2016 | ($4.20M) | +66.36% |
| Q1 2016 | ($12.48M) | +54.33% |
| Q4 2015 | ($27.33M) | (44.38%) |
| Q3 2015 | ($18.93M) | (22.65%) |
| Q2 2015 | ($15.43M) | (30.40%) |
| Q1 2015 | ($11.83M) | (119.15%) |
| Q4 2014 | ($5.40M) | +50.21% |
| Q3 2014 | ($10.85M) | +62.75% |
| Q2 2014 | ($29.11M) | (373.81%) |
| Q1 2014 | ($6.14M) | (145.76%) |
| Q4 2013 | ($2.50M) | +88.26% |
| Q3 2013 | ($21.29M) | (102.40%) |
| Q2 2013 | ($10.52M) | +1.37% |
| Q1 2013 | ($10.66M) | (4.62%) |
| Q4 2012 | ($10.19M) | +17.90% |
| Q3 2012 | ($12.42M) | +14.22% |
| Q2 2012 | ($14.48M) | +2.06% |
| Q1 2012 | ($14.78M) | (3.09%) |
| Q4 2011 | ($14.34M) | (5.71%) |
| Q3 2011 | ($13.56M) | +30.18% |
| Q2 2011 | ($19.42M) | (97.23%) |
| Q1 2011 | ($9.85M) | +52.79% |
| Q4 2010 | ($20.86M) | (72.38%) |
| Q3 2010 | ($12.10M) | +11.75% |
| Q2 2010 | ($13.71M) | +1.04% |
| Q1 2010 | ($13.86M) | +7.21% |
| Q4 2009 | ($14.93M) | +39.61% |
| Q3 2009 | ($24.73M) | (22.17%) |
| Q2 2009 | ($20.24M) | (3.02%) |
| Q1 2009 | ($19.64M) | +30.54% |
| Q4 2008 | ($28.28M) | (36.29%) |
| Q3 2008 | ($20.75M) | +13.11% |
| Q2 2008 | ($23.88M) | (20.17%) |
| Q1 2008 | ($19.87M) | (26.84%) |
| Q4 2007 | ($15.67M) | (14.88%) |
| Q3 2007 | ($13.64M) | (7.63%) |
| Q2 2007 | ($12.67M) | (9.62%) |
| Q1 2007 | ($11.56M) | (6.25%) |
| Q4 2006 | ($10.88M) | (30.19%) |
| Q3 2006 | ($8.36M) | +0.00% |
| Q2 2006 | ($8.36M) | +0.00% |
| Q1 2006 | ($8.36M) | (28.29%) |
| Q4 2005 | ($6.51M) | (29.22%) |
| Q3 2005 | ($5.04M) | +0.00% |
| Q2 2005 | ($5.04M) | +0.00% |
| Q1 2005 | ($5.04M) | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy